Knockdown of the T-box transcription factor brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro: Implications for a new therapeutic principle

Yosuke Kobayashi, Tsuyoshi Sugiura, Ikumi Imajyo, Miyuki Shimoda, kotaro ishii, Naonari Akimoto, Naoya Yoshihama, Yoshihide Mori

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Adenoid cystic carcinoma (AdCC) is highly metastatic and resistant to chemotherapy and radiotherapy. Recently, we reported that the T-box transcription factor Brachyury is a potential regulator of cancer stem cells (CSCs). Specifically, growth of CSCs was found to be controlled by Brachyury knockdown in AdCC. Since CSCs are resistant to chemotherapy and radiotherapy, this finding provides a new principle for therapies targeting CSCs. In the present study, we established that Brachyury knockdown suppresses chemoresistance and radioresistance in vitro. Brachyury was knocked down by transfecting Brachyury short hairpin RNA (shRNA) into the AdCC CSC cell line ACCS-M GFP. Brachyury knockdown significantly inhibited cell migration and invasion and suppressed chemoresistance. A quantitative PCR array of drug transporter genes revealed that knockdown of Brachyury caused down regulation of ATP-binding cassette transporter genes. Furthermore, ACCS-M GFP radioresistance was significantly suppressed by Brachyury knockdown. Knockdown of Brachyury significantly sensitized ACCS-M GFP cells to chemoradiotherapy. This study demonstrates that Brachyury knockdown reduces invasiveness and chemoresistance and radioresistance of CSCs in vivo. Therefore, Brachyury knockdown may be a useful therapeutic tool for sensitizing CSCs to conventional chemoradiotherapy.

Original languageEnglish
Pages (from-to)1107-1117
Number of pages11
JournalInternational journal of oncology
Volume44
Issue number4
DOIs
Publication statusPublished - Apr 1 2014

Fingerprint

Adenoid Cystic Carcinoma
Transcription Factors
Neoplastic Stem Cells
Radiation
Drug Therapy
Therapeutics
Chemoradiotherapy
Brachyury protein
In Vitro Techniques
Radiotherapy
Gene Knockdown Techniques
ATP-Binding Cassette Transporters
Small Interfering RNA
Cell Movement
Down-Regulation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Knockdown of the T-box transcription factor brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro : Implications for a new therapeutic principle. / Kobayashi, Yosuke; Sugiura, Tsuyoshi; Imajyo, Ikumi; Shimoda, Miyuki; ishii, kotaro; Akimoto, Naonari; Yoshihama, Naoya; Mori, Yoshihide.

In: International journal of oncology, Vol. 44, No. 4, 01.04.2014, p. 1107-1117.

Research output: Contribution to journalArticle

@article{60309d6c487246bdb5730dabb6932413,
title = "Knockdown of the T-box transcription factor brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro: Implications for a new therapeutic principle",
abstract = "Adenoid cystic carcinoma (AdCC) is highly metastatic and resistant to chemotherapy and radiotherapy. Recently, we reported that the T-box transcription factor Brachyury is a potential regulator of cancer stem cells (CSCs). Specifically, growth of CSCs was found to be controlled by Brachyury knockdown in AdCC. Since CSCs are resistant to chemotherapy and radiotherapy, this finding provides a new principle for therapies targeting CSCs. In the present study, we established that Brachyury knockdown suppresses chemoresistance and radioresistance in vitro. Brachyury was knocked down by transfecting Brachyury short hairpin RNA (shRNA) into the AdCC CSC cell line ACCS-M GFP. Brachyury knockdown significantly inhibited cell migration and invasion and suppressed chemoresistance. A quantitative PCR array of drug transporter genes revealed that knockdown of Brachyury caused down regulation of ATP-binding cassette transporter genes. Furthermore, ACCS-M GFP radioresistance was significantly suppressed by Brachyury knockdown. Knockdown of Brachyury significantly sensitized ACCS-M GFP cells to chemoradiotherapy. This study demonstrates that Brachyury knockdown reduces invasiveness and chemoresistance and radioresistance of CSCs in vivo. Therefore, Brachyury knockdown may be a useful therapeutic tool for sensitizing CSCs to conventional chemoradiotherapy.",
author = "Yosuke Kobayashi and Tsuyoshi Sugiura and Ikumi Imajyo and Miyuki Shimoda and kotaro ishii and Naonari Akimoto and Naoya Yoshihama and Yoshihide Mori",
year = "2014",
month = "4",
day = "1",
doi = "10.3892/ijo.2014.2292",
language = "English",
volume = "44",
pages = "1107--1117",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Knockdown of the T-box transcription factor brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro

T2 - Implications for a new therapeutic principle

AU - Kobayashi, Yosuke

AU - Sugiura, Tsuyoshi

AU - Imajyo, Ikumi

AU - Shimoda, Miyuki

AU - ishii, kotaro

AU - Akimoto, Naonari

AU - Yoshihama, Naoya

AU - Mori, Yoshihide

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Adenoid cystic carcinoma (AdCC) is highly metastatic and resistant to chemotherapy and radiotherapy. Recently, we reported that the T-box transcription factor Brachyury is a potential regulator of cancer stem cells (CSCs). Specifically, growth of CSCs was found to be controlled by Brachyury knockdown in AdCC. Since CSCs are resistant to chemotherapy and radiotherapy, this finding provides a new principle for therapies targeting CSCs. In the present study, we established that Brachyury knockdown suppresses chemoresistance and radioresistance in vitro. Brachyury was knocked down by transfecting Brachyury short hairpin RNA (shRNA) into the AdCC CSC cell line ACCS-M GFP. Brachyury knockdown significantly inhibited cell migration and invasion and suppressed chemoresistance. A quantitative PCR array of drug transporter genes revealed that knockdown of Brachyury caused down regulation of ATP-binding cassette transporter genes. Furthermore, ACCS-M GFP radioresistance was significantly suppressed by Brachyury knockdown. Knockdown of Brachyury significantly sensitized ACCS-M GFP cells to chemoradiotherapy. This study demonstrates that Brachyury knockdown reduces invasiveness and chemoresistance and radioresistance of CSCs in vivo. Therefore, Brachyury knockdown may be a useful therapeutic tool for sensitizing CSCs to conventional chemoradiotherapy.

AB - Adenoid cystic carcinoma (AdCC) is highly metastatic and resistant to chemotherapy and radiotherapy. Recently, we reported that the T-box transcription factor Brachyury is a potential regulator of cancer stem cells (CSCs). Specifically, growth of CSCs was found to be controlled by Brachyury knockdown in AdCC. Since CSCs are resistant to chemotherapy and radiotherapy, this finding provides a new principle for therapies targeting CSCs. In the present study, we established that Brachyury knockdown suppresses chemoresistance and radioresistance in vitro. Brachyury was knocked down by transfecting Brachyury short hairpin RNA (shRNA) into the AdCC CSC cell line ACCS-M GFP. Brachyury knockdown significantly inhibited cell migration and invasion and suppressed chemoresistance. A quantitative PCR array of drug transporter genes revealed that knockdown of Brachyury caused down regulation of ATP-binding cassette transporter genes. Furthermore, ACCS-M GFP radioresistance was significantly suppressed by Brachyury knockdown. Knockdown of Brachyury significantly sensitized ACCS-M GFP cells to chemoradiotherapy. This study demonstrates that Brachyury knockdown reduces invasiveness and chemoresistance and radioresistance of CSCs in vivo. Therefore, Brachyury knockdown may be a useful therapeutic tool for sensitizing CSCs to conventional chemoradiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84894428819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894428819&partnerID=8YFLogxK

U2 - 10.3892/ijo.2014.2292

DO - 10.3892/ijo.2014.2292

M3 - Article

C2 - 24504414

AN - SCOPUS:84894428819

VL - 44

SP - 1107

EP - 1117

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -